

PRODUCT MONOGRAPH

FLUOROURACIL INJECTION USP

5-fluorouracil Ph.Eur.

50 mg/mL Injection USP

Antineoplastic Agent

Sandoz Canada Inc.
145 Jules-Léger
Boucherville, QC
J4B 7K8

Date of Revision: April 16, 2012

Submission Control No: 145218

Fluorouracil Injection USP

(5-fluorouracil Ph.Eur.)

THERAPEUTIC CLASSIFICATION

Antineoplastic

CAUTION: FLUOROURACIL (5-FLUOROURACIL) IS A POTENT DRUG AND SHOULD BE PRESCRIBED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE WARNINGS AND PRECAUTIONS). BLOOD COUNTS AS WELL AS RENAL AND HEPATIC FUNCTION TESTS SHOULD BE PERFORMED REGULARLY. DISCONTINUE THE DRUG IF THERE IS SIGNIFICANT LEUKOPENIA (UNDER 3000/mm³) OR GRANULOCYTOPENIA (UNDER 1500/mm³).

ACTIONS AND CLINICAL PHARMACOLOGY

Fluorouracil (5-fluorouracil) is a fluorinated pyrimidine antimetabolite which is structurally similar to uracil, one of the necessary building blocks in cellular division and growth.




Figure 1

Its usefulness is based on uracil being utilized preferentially for nucleic acid biosynthesis in some tumors. 5-fluorouracil is metabolized to 5-fluorouridine triphosphate (F-UTP), 2-deoxyfluorouridine monophosphate (Fd-Ump), and 2-deoxyfluorouridine triphosphate (Fd-UTP) in cells to concentrations that result in both DNA-directed and RNA-directed cytotoxicities (see Figure 1). Fd-Ump is the intracellular cytotoxic form of 5-fluorouracil. It competes with the natural substrate d-Ump (deoxyuridine monophosphate) for the catalytic site

on thymidylate synthetase (a key enzyme in DNA synthesis), forming a covalent complex with the enzyme that is unable to undergo the normal catalytic reaction of converting d-UMP to d-TMP. The presence of a reduced folate cofactor is required for tight binding of Fd-UMP to thymidylate synthetase. Folinic acid (leucovorin), which is metabolized to 5,10-methylene-tetrahydropteroylglutamine (a reduced folate), is able to modulate the antineoplastic effect of 5-fluorouracil by promoting the formation and stabilization of the ternary complex formed between Fd-UMP and thymidylate synthetase. In this way, leucovorin produces a synergistic effect on 5-fluorouracil therapy.

At the same time, 5-fluorouracil interferes with the mechanism of action of RNA, resulting from the formation of «fraudulent» RNA by the incorporation of F-UTP in the ribonucleotides. Incorporation into RNA has been associated with toxicity and has major effects on both the processing and functions of RNA.

By interference with the formation of DNA and RNA, 5-fluorouracil provokes unbalanced growth and death of cells. The effects of DNA and RNA deprivation are most marked on those cells which grow rapidly and which take up 5-fluorouracil rapidly.

While there is no evidence that 5-fluorouracil prolongs survival time generally, the usefulness of the drug has been demonstrated by the relief of pain and other symptoms in certain types of human malignancies. There have also occasionally been regression of tumors.

The steady-state plasma concentrations of 5-fluorouracil following bolus IV doses of 400-600 mg/m² (10-15 mg/kg) range from 0.1-1.0 mM. Following continuous infusion of 1100 mg/m²/day, plasma concentrations of 0.5-2.5 mcM are observed. 5-fluorouracil readily penetrates the blood-brain barrier and CSF concentrations of about 7 mcM are reached within 30 minutes after intravenous administration. The volume of distribution of 5-fluorouracil ranges from 0.1 to 0.4 L/kg. The elimination half-life is 6-20 minutes and is dose-dependent. Following an IV injection, no intact drug can be detected in the plasma after three hours. For bolus doses, 5-fluorouracil plasma clearance is 0.5 to 1.4 L/min. Clearance values are 10- to 60-fold higher following IV infusion. This non-linearity likely represents saturation of a metabolic or transport process at higher drug concentrations. Plasma protein binding of 5-fluorouracil is 10%.

The metabolism of 5-fluorouracil occurs mainly in the liver and results in degradation products (e.g., carbon dioxide, urea, alpha-fluoro-beta-alanine) which are inactive. Approximately 15% of the dose is excreted intact in the urine in 6 hours and over 90% of this is excreted intact in the first hour; 60 to 80% is excreted as respiratory carbon dioxide in 8 to 12 hours.

INDICATIONS AND CLINICAL USE

Fluorouracil Injection USP (5-fluorouracil) is indicated in the palliative management of carcinoma of the breast, colon, rectum, stomach and pancreas. In clinical practice, 5-fluorouracil is often combined with other cytotoxic agents such as methotrexate, cyclophosphamide, cisplatin, vincristine, mitomycin, adriamycin, levamisole and interferon alpha-2a; or drugs which may enhance its effect on killing tumor cells such as calcium leucovorin.

Various combinations of 5-fluorouracil/interferon and 5-fluorouracil/leucovorin/interferon are also used in clinical practice.

Fluorouracil Injection USP does not replace surgery or other recognized forms of therapy and should be used only when these measures are not possible or have been tried and have failed.

CONTRAINDICATIONS

Fluorouracil (5-fluorouracil) therapy is contraindicated in pregnant women, for patients in a poor nutritional state, those with severely depressed bone marrow function, with potentially serious infections, or those with a known hypersensitivity to 5-fluorouracil.

WARNINGS

Fluorouracil (5-fluorouracil) should be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and well-versed in the use of potent antimetabolites.

The drug should be used with extreme caution in patients who have undergone recent major surgery; those with a history of high dose irradiation to bone marrow-bearing areas (pelvis, spine, ribs, etc.) or previous use of other myelosuppressive chemotherapeutic agents; those with a widespread involvement of bone marrow by metastatic tumors; or those with renal or liver impairment. Although severe toxicity is more likely in debilitated patients, fatalities may be encountered occasionally even in patients in relatively good condition.

5-fluorouracil should be used with great care in patients who are known or suspected to have a dihydropyrimidine dehydrogenase deficiency, as these patients are at a greater risk of experiencing symptoms of toxicity.

Usage in Pregnancy: Although it is not known whether 5-fluorouracil crosses the human placenta, it has been shown to cross the rat placenta and enter into the fetal circulation of this rodent. Positive teratologic findings have been observed in animals (see TOXICOLOGY, Teratology). Therefore, this drug should not be used during pregnancy.

Nursing Mothers: It is not known whether 5-fluorouracil is excreted in human milk. Because 5-fluorouracil inhibits DNA, RNA and protein synthesis, mothers should not nurse while receiving this drug.

Mutagenesis: Positive mutagenic findings have been observed in the usual mutagenicity screening tests (see TOXICOLOGY, Mutagenicity).

Drug Interactions - Combined Therapy

Leucovorin (folinic acid) and 5-fluorouracil are routinely used together in the treatment of colorectal cancer. There is biochemical rationale for the synergism produced by the combination of 5-fluorouracil and leucovorin. Leucovorin is metabolized to a reduced folate co-factor that is necessary for maximal inhibition of thymidylate synthetase by Fd-UMP, the active metabolite of 5-fluorouracil. Studies with tumour lines *in vitro* have confirmed this effect and several clinical studies have shown evidence that there may be some increased therapeutic benefit from providing a source of reduced folate.

Clinical trials have been reported using sequenced methotrexate/fluorouracil in head and neck, breast and colorectal cancers. Methotrexate has been shown to improve the effectiveness of 5-fluorouracil against tumor cells *in vitro* and *in vivo*. The sequence of administration is of importance. Administration of methotrexate followed by 5-fluorouracil leads to a synergistic interaction. Biochemical modulation might occur both through effects on RNA and DNA synthesis and enhancement of 5-fluorouracil uptake. The importance of the time interval between methotrexate and 5-fluorouracil exposure in the treatment of metastatic colon cancer has been demonstrated. When these two agents are separated by 24 hours as compared with 1 hour, the response rate, time to progression and survival are significantly improved. However, different tumors may respond differently to changes in the time interval between methotrexate and 5-fluorouracil.

Any form of therapy which adds to the stress of the patient, interferes with nutrition, or depresses bone marrow function, may increase the toxicity of 5-fluorouracil.

When combining 5-fluorouracil with other anticancer agents (such as methotrexate, cyclophosphamide, cisplatin, vincristine, mitomycin, adriamycin, levamisole or interferon alpha-2a) and leucovorin, drug interactions increasing both the efficacy and/or toxicity have been reported. A hemolytic-uremic syndrome has been reported to occur after long-term use of 5-fluorouracil in combination with mitomycin.

PRECAUTIONS

Fluorouracil (5-fluorouracil) should be administered by individuals experienced in the use of antineoplastic therapy. Fluorouracil is both an irritant and a highly toxic drug. Professional staff administering 5-fluorouracil should exercise particular care to prevent spillage and contact with the drug. Should skin contact occur, the area should be vigorously washed with soap and cold water and the material used for cleansing disposed by incineration. In the case of contact with the eyes, irrigate immediately with water and contact a physician. If inhaled or ingested, seek immediate medical attention. (see PHARMACEUTICAL INFORMATION, Special Instructions).

5-fluorouracil is a highly toxic drug with a narrow margin of safety. Therefore, patients should be carefully supervised. Therapy should be properly adjusted or discontinued if:

- Significant stomatitis, mucositis or esophagitis, severe diarrhea or vomiting, or gastrointestinal ulcers or bleeding occurs.
- Leukopenia (WBC count under $3000/\text{mm}^3$), thrombocytopenia (platelet count under $80\,000/\text{mm}^3$), or granulocytopenia (under $1500/\text{mm}^3$).
- Central or peripheral nervous system toxicity, including ataxia, tremor.
- Cardiac toxicity.

Therapeutic response is unlikely to occur without some evidence of toxicity. Patients should be informed of expected toxic effects, particularly oral manifestations (see Adverse Reactions).

Because of the possibility of leukopenia, frequent blood counts (every two or three days) are essential during initial therapy. If the count falls, it is advisable to obtain differentials with each count. If the count is less than $1500/\text{mm}^3$ with marked granulocytopenia (less than $1000/\text{mm}^3$), it is recommended that the patient be carefully followed and considered for prophylactic antibiotics. During maintenance therapy, counts before each course are sufficient.

In the case of severe gastrointestinal, cardiac or neurological toxicity, continued treatment with 5-fluorouracil is not recommended.

Severe hematological effects, gastrointestinal hemorrhage and even death may result from the use of 5-fluorouracil despite meticulous selection of patients and careful adjustment of dosage, but severe toxicity is more frequent in poor risk patients.

Laboratory Test Interactions

The results of tests for bilirubin (icteric index), and for 5-hydroxyindole acetic acid in the urine, may be increased or false positive.

ADVERSE REACTIONS

Stomatitis, mucositis and esophagopharyngitis (which may lead to sloughing and ulceration), diarrhea, anorexia, nausea and emesis are commonly seen during therapy with Fluorouracil (5-fluorouracil). Allergic reactions including anaphylaxis, bronchospasm, urticaria and pruritus have also been reported. If anaphylactic shock occurs, the usual countermeasures should be employed. Diarrhea usually responds to antidiarrheal agents. Uncontrolled nausea and vomiting can be treated with antiemetic agents.

Leukopenia with neutropenia usually follows each course of adequate therapy with 5-fluorouracil. The lowest white blood cell counts are commonly observed between the 9th and 14th days after the first dose, although the maximal depression may occasionally be delayed for as long as 20 days. By the 30th day, the count usually returns to the normal range. Pancytopenia, agranulocytosis, anemia, hemolytic anemia and thrombocytopenia have also been reported. Due to immunosuppression, infections (sometimes serious), may develop in patients treated with 5-fluorouracil.

Alopecia and dermatitis may be seen in a substantial number of cases. Patients should be alerted to the possibility of alopecia, but since the alopecia is reported to be reversible, special measures do not seem to be indicated. The dermatitis seen most often is a pruritic maculopapular rash appearing usually on the extremities and sometimes on the trunk. It is generally reversible and responsive to symptomatic treatment.

Other Adverse Reactions

Cardiovascular: Myocardial ischemia, angina, precordial pain, cardiac arrhythmias, ischemia and heart failure resulting rarely in death.

Gastrointestinal: Gastrointestinal ulceration and bleeding.

Central nervous system: Ataxia, dysarthria, nystagmus, disorientation, headache, confusion, euphoria, acute cerebellar syndrome (which may persist following discontinuation of treatment). Extra pyramidal or cortical dysfunction (usually reversible). Isolated cases of leucoencephalopathy have also been reported.

Dermatologic: Dry skin; fissuring; photosensitivity as manifested by erythema or increased pigmentation of the skin; palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), as manifested by tingling of the hands and feet followed by pain, erythema and swelling. Palmar-plantar erythrodysesthesia syndrome gradually resolves 5 to 7 days after interruption of therapy. This syndrome may be treated with the concomitant oral administration of pyridoxine at doses of 100 to 150 mg per day.

Ophthalmic: Visual changes; photophobia; oculomotor disturbances and lacrimation, optic neuritis. Lacrimal duct stenosis (canalicular fibrosis) associated with prolonged administration of fluorouracil has been reported as rare. This condition is reversible upon reduction or temporary cessation of 5-fluorouracil therapy, but on occasion may necessitate surgical intervention.

Miscellaneous: Thrombophlebitis, epistaxis, nail changes (including loss of nails), chest pain, vein pigmentation. Hepatocellular damage and, in very rare cases, fatal hepatic necrosis have been observed.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

Report online at www.healthcanada.gc.ca/medeffect

Call toll-free at 1-866-234-2345

Complete a Canada Vigilance Reporting Form and:

- Fax toll-free to 1-866-678-6789, or
- Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701E
Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

SYMPTOMS AND TREATMENT OF OVERDOSE

The main symptoms of overdose are nausea, vomiting, diarrhea, stomatitis, esophagopharyngitis, gastrointestinal ulceration and bleeding, hemorrhage from any site and bone marrow depression (including thrombocytopenia, leukopenia and agranulocytosis). No specific antidotal therapy exists. Patients who have been exposed to an overdose of Fluorouracil (5-fluorouracil) should be monitored hematologically with regular white cell counts, differentials and platelet counts. Should abnormalities appear, appropriate symptomatic therapy should be utilized. Suitable counter measures are withdrawal of medication or dosage reduction and, depending on the symptoms, blood transfusions, leukocyte or platelet infusions or antiinfective therapy. Nausea, vomiting and diarrhea may be controlled by appropriate therapy.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

DOSAGE AND ADMINISTRATION

Criteria for the selection of patients: In order to be considered for Fluorouracil Injection USP (5-fluorouracil) therapy, a prospective patient must meet the following:

1. No history of high irradiation to major bone marrow-bearing areas.
Adequate bone marrow function, i.e., a white blood cell count of $3000/\text{mm}^3$ or over, a granulocyte count of $1500/\text{mm}^3$ or over and a platelet count of $80\,000/\text{mm}^3$ or over.
2. Adequate hepatic and renal functions.

Fluorouracil Injection USP (5-fluorouracil) should only be administered intravenously, and care should be taken to avoid extravasation. No dilution of the solution is required when Fluorouracil Injection USP is given by direct intravenous injection.

In most cases, dosage should be based on the patient's actual weight or actual body surface area. However, if the patient is obese or if there has been a spurious weight gain due to edema, ascites

or other forms of abnormal fluid retention, the ideal weight or ideal body surface area should be used. Following major weight loss, the dose of 5-fluorouracil should be reduced.

It is recommended that each patient be carefully evaluated prior to treatment, in order to estimate as accurately as possible the optimum initial dosage of Fluorouracil Injection USP. Likewise, the duration of therapy must be determined by a specialist, based on the type and course of the disease.

Dosage: The following dosage schedules may be used.

General Recommendations

IV Injection

1. 800 mg/m² (19 mg/kg) single dose.
2. 480 mg/m² (12 mg/kg) per day on days 1, 2, 3, 4 followed by 240 mg/m² (6 mg/kg) per day on days 6, 8, 10 and 12. Repeat course every 30 days.
3. 300-450 mg/m² (7-11 mg/kg) per day for 5 days. Repeat every 4 weeks.
4. 400-480 mg/m² (10-12 mg/kg) or 500-600 mg/m² (12-15 mg/kg) per week.

IV Infusion

Administration by infusion may result in slightly less toxicity. Fluorouracil Injection USP may be diluted with 300 to 500 mL of 5% dextrose solution.

1. 480 mg/m² (12 mg/kg) over a period of 4 hours daily until signs of toxicity are observed, usually within 8 to 15 days.
2. 1000-2000 mg/m² (24-49 mg/kg) over a period of 24 hours daily for 5 days. Repeat course every 4 weeks.

Combination therapy with folinic acid

IV injection 370-400 mg/m² (9-10 mg/kg) for 5 days plus folinic acid 200-500 mg/m² (5-12 mg/kg) for 5 days. Repeat course every 4 weeks.

The patient must be monitored for toxic signs. Drug therapy should be appropriately adjusted or discontinued should toxic signs such as gastrointestinal bleeding become manifested.

Recommendations for Poor Risk Patients

For poor risk patients, the following dosage schedules may be used:

IV Injection

240 mg/m² (6 mg/kg) per day on days 1, 2, 3 followed by 120 mg/m² (3 mg/kg) per day on days 5, 7, 9. Repeat course every 30 days.

IV Infusion

240 mg/m² (6 mg/kg) over a period of 4 hours daily until signs of toxicity are observed, usually within 8 to 15 days.

Renal Impairment:

Due to the impairment of bone marrow function in azotemia, secondary to kidney failure, a dose adjustment appropriate to the degree of renal failure and to the reaction of the individual patient to Fluorouracil Injection USP is recommended.

Liver Impairment:

Since 5-fluorouracil is metabolized mainly in the liver, a dosage reduction should be considered when liver function is impaired.

Note: The patient's reaction to the previous course should be taken into account when determining the dosage. Some patients have received from 9 to 45 courses of treatment over periods ranging from 12 to 60 months.

Frequent blood counts (every two or three days) are essential during initial therapy. During maintenance therapy, counts before each course are sufficient.

Therapy should be properly adjusted or discontinued whenever any of the following signs of toxicity appear:

- Significant stomatitis, mucositis or esophagitis, severe diarrhea or vomiting, or gastrointestinal ulcers or bleeding occurs.
- Leukopenia (WBC count under $3000/\text{mm}^3$), thrombocytopenia (platelet count under $80\,000/\text{mm}^3$), or granulocytopenia (under $1500/\text{mm}^3$).
- Central or peripheral nervous system toxicity, including ataxia, tremor.
- Cardiac toxicity.


Dosage Reduction in Combination Therapy:

When Fluorouracil Injection USP is combined with other cytostatics of similar toxicity profile or with radiotherapy, the recommended dosage should be reduced accordingly.

PHARMACEUTICAL INFORMATION

Drug Substance:

Common Name: Fluorouracil Ph.Eur.
Chemical Name: 5-fluoro-2,4 (1H, 3H)-pyrimidinedione
Structural Formula:



Molecular Formula: $C_4H_3FN_2O_2$
Molecular Weight: 130.08
Physical Form: White to almost white, almost odourless, crystalline powder.
Solubility: Sparingly soluble in water, slightly soluble in alcohol, almost insoluble in chloroform and ether.

COMPOSITION

Fluorouracil Injection USP contains 50 mg of fluorouracil Ph.Eur. per mL of water for injection; sodium hydroxide is added to solubilize the compound and to adjust the pH to approximately 9.2.

STABILITY AND STORAGE RECOMMENDATIONS

Store between 15 and 30°C. Protect from light. Do not freeze.

Although Fluorouracil Injection USP (5- fluorouracil) solution may discolour slightly during storage, the potency, and safety are not adversely affected, and are maintained until the expiry date.

If a precipitate occurs during storage, resolubilize by heating to 60°C with vigorous shaking; allow to cool to body temperature before using.

Dilution:

No dilution of the solution is required when Fluorouracil Injection USP is given by direct intravenous injection.

Fluorouracil Injection USP may be diluted with 300 to 500 mL of 5% dextrose and administered by infusion over a period of either 4 or 24 hours (see Dosage and Administration). Infusions prepared with 5% dextrose solution should be used within 24 hours.

Special Instructions:

1. As for all antineoplastic agents, personnel handling these agents should wear polyvinylchloride gloves, safety glasses, disposable gowns and masks and should work in vertical laminar flow hood.
2. Fluorouracil is both an irritant and a highly toxic drug. Professional staff administering antineoplastic agents should exercise particular care to prevent spillage and contact with the drug. Should skin contact occur, the area should be vigorously washed with soap and water. In the case of contact with the eyes, irrigate immediately with water and contact a physician. If inhaled or ingested, seek immediate medical attention.
3. As 5-fluorouracil is frequently adsorbed by regular glass surfaces, silanized glass should be used when 5-fluorouracil is given. All materials which have come in contact with cytotoxic agents including needles, syringes, open ampoules or vials, polyvinylchloride gloves, gowns, masks and materials used for cleansing, should be segregated and incinerated at 1000°C or more. If incineration is not possible, add household bleach (sodium hypochlorite solution) or 0.1 molar sodium hydroxide solution and place the sealed container in a landfill site.
4. Personnel regularly involved in the preparation and handling of cytotoxic agents should have bi-annual blood examinations.

AVAILABILITY

Fluorouracil Injection USP is available in:

10 mL single-dose vials containing 500 mg fluorouracil, in packs of 5 vials.

100 mL Pharmacy bulk vial containing 5 000 mg fluorouracil, in packs of 1 vial.

LATEX-FREE stoppers: stoppers contain no dry natural rubber

PHARMACOLOGY

Animals

5-fluorouracil has wide range of activity against the majority of solid and ascitic forms of epithelial and mesenchymal transplantable tumors of mice, rats and hamsters. Examples of these transplantable tumors include Flexner-Jobling carcinoma, Walker 256 carcinoma, Yoshida ascites tumor, Shay's chloroleukemia, Sarcoma 180, Ehrlich ascites carcinoma, L-1210 leukemia, E0771, mammary adeno-carcinoma 755 and Sarcoma A-1. 5-fluorouracil is ineffective in

spontaneous mammary tumors, human epidermoid carcinoma, Harding-Passey melanoma, myeloid leukemia Db 1490, and 5-fluorouracil resistant strains of Ehrlich carcinoma and leukemia L-1210.

Tissue Cultures

5-fluorouracil inhibits the growth of HeLa and H. Ep. #1 cells, both of which are epithelial-like stains derived from human cervical carcinomas, in tissue culture. The minimum active concentration inhibiting the growth of HeLa cells ranges from 0.1 to 1.0 mcg/mL depending on the media used in the study. For H. Ep. #1 cells, the minimum active concentration is 1.0 mcg/mL.

Microorganisms

5-fluorouracil is a potent inhibitor of the growth of the bacteria, *Lactobacillus leichmannii*, *Lactobacillus plantarum*, *Lactobacillus casei* and *Streptococcus faecalis*, and the yeast, *Saccharomyces carlsbergensis*. The mode of action of 5-fluorouracil in these microorganisms appears to be that the drug is converted into 5-fluoro-2'-deoxyuridylic acid, a highly potent irreversible inhibitor of the enzyme thymidylate synthetase, the catalyst needed in the methylation of deoxyuridylic acid to thymidylic acid, an important reaction in the formation of DNA.

Humans

In man, the biochemical effects of 5-fluorouracil in the anabolic pathway are:

1. Inhibition of the incorporation of uracil and orotic acid in the synthesis of RNA thus inhibiting its synthesis.
2. Synthesis of an unnatural RNA by incorporation of 5-fluorouracil into the molecule.
3. Inhibition of the methylation of deoxyuridylic acid to thymidylic acid thereby inhibiting the synthesis of DNA.

5-fluorouracil is converted into fluorouridine and further into the mono-, di-, and triphosphates of fluorouridine. 5-fluorouridine monophosphate is then reduced to 5-fluoro-2'-deoxyuridine monophosphate, the apparent lethal nucleotide, which inhibits the enzyme thymidylate synthetase required in the DNA synthesis. The inhibition of DNA synthesis is considered to be chiefly responsible for the antineoplastic activity of 5-fluorouracil in man, since concentrations which inhibit DNA still permit RNA synthesis.

The catabolic pathway of 5-fluorouracil is analogous to that of uracil, forming the following degradative products: dihydrofluorouracil, alpha-fluoro-beta-ureidopropionic acid, alpha-fluoro-beta-guanidopropionic acid, alpha-fluoro-beta-alanine, urea, and CO₂.

TOXICOLOGY

Short-Term Toxicity

LD₅₀ values of 5-fluorouracil in difference species via different routes of administration are as follows:

Species	LD ₅₀ (mg/kg ± S.E.)			
	IV	SC	IP	PO
Mice	340 ± 17	> 250	> 500	266 ± 25
Rats	165 ± 26	--	230	303 ± 51
Rabbits	27 ± 5.1	--	--	24 ± 1.9
Dogs	31.5 ± 3.8	--	--	29 ± 3.1

The toxicity of 5-fluorouracil shows pronounced species differences. Dogs, cats and rabbits display acute intoxication resembling fluoroacetate poisoning. Convulsions are observed in cats and dogs while cardiac failure appears in rabbits. Mice, rats and monkeys tolerate 5-fluorouracil better than dogs, cats and rabbits.

Long-Term Toxicity

Excessive dosage of 5-fluorouracil in mice, rats and monkeys leads to chronic intoxication characterized by depression of cells of the bone marrow and damage to cells of the gastrointestinal mucosa. The bone marrow damage caused by overdosage is reversible upon discontinuation of 5-fluorouracil.

The approximate doses which are tolerated for varying periods of time in different species are shown in the following table:

Species	Dose (mg/kg/day)	No. of Days	Route of Administration
Mice	25	14	SC
Rats	6-12	14	SC
Rabbits	2.5	30	SC
Dogs	3-12 ^a	65 ^b	SC

- a) One of the three monkeys receiving 12 mg/kg/day demonstrated severe toxicity and had to be sacrificed after 6 weeks of treatment.
b) Five days/week dosing for 13 consecutive weeks.

Carcinogenicity

Animal studies have demonstrated an increased incidence of some tumors in mice, but not in rats, after long-term treatment with 5-fluorouracil. Fifty male and fifty female BALB/C mice were administered 5-fluorouracil IP at a dose of 30 mg/kg body weight once a week to test the carcinogenicity of 5-fluorouracil. A significant increase in lung tumors in both sexes and tumors of the lymphoreticular system in female mice was observed.

No evidence of carcinogenicity was reported in four groups of Fischer rats administered 5-fluorouracil by gastric intubation 5 times per week for 52 weeks, at a dose of 3.0, 1.0, 0.01 and 0.3 mg/animal per day followed by a 6 month observation period. In another study, male BR46 rats were administered weekly with IV injections of 33 mg/kg body weight for 52 weeks, followed by observations for the remainder of their lifetimes with no evidence of carcinogenesis.

Mutagenicity

Oncogenic transformation of fibroblasts from mouse embryo has been induced *in vitro* by 5-fluorouracil, but the relationship between oncogenicity and mutagenicity is not clear. 5-fluorouracil is mutagenic to several strains of *Salmonella typhimurium*, including TA 1535, TA 1537 and TA 1538, and to *Saccharomyces cerevisiae*, although no evidence of mutagenicity was found with *Salmonella typhimurium* strains TA 92, TA 98 and TA 100. A positive effect was observed in the micronucleus test on bone marrow cells of the mouse. 5-fluorouracil, at very high concentrations, produced chromosomal breaks in hamster fibroblasts *in vitro*.

Reproduction

5-fluorouracil has not been adequately studied in animals to permit an evaluation of its effects on fertility and general reproductive performance. However, doses of 125 or 250 mg/kg, administered intraperitoneally, have been shown to induce chromosomal aberrations and changes in chromosomal organization of spermatogonia in rats. Spermatogonial differentiation was also inhibited by 5-fluorouracil, resulting in transient infertility. However, in studies with a strain of mouse which is sensitive to the induction of sperm head abnormalities after exposure to a range of chemical mutagens and carcinogens, 5-fluorouracil did not produce any abnormalities at oral doses of up to 80 mg/kg/day. In female rats, 5-fluorouracil, administered intraperitoneally at weekly doses of 25 or 50 mg/kg for three weeks during the pre-ovulatory phase of oogenesis, significantly reduced the incidence of fertile matings, delayed the development of pre- and post-implantation embryos, increased the incidence of pre-implantation lethality and induced chromosomal anomalies in these embryos. In the limited study in rabbits, a single 25 mg/kg dose of 5-fluorouracil or 5 daily doses of 5 mg/kg had no effect on ovulation, appeared not to affect implantation and had only a limited effect in producing zygote destruction. Agents such as 5-fluorouracil, which interfere with DNA, RNA and protein synthesis, might be expected to have adverse effects on gametogenesis.

Teratology

5-fluorouracil is teratogenic in laboratory animals. 5-fluorouracil exhibited maximum teratogenicity when given to mice as single intraperitoneal injections of 10 to 40 mg/kg on day 10 or 12 of gestation. Similarly, intraperitoneal doses of 12 to 37 mg/kg given to rats between days 9 and 12 of gestation and intramuscular doses of 3 to 9 mg given to hamsters between days 8 and 11 of gestation were teratogenic. Malformations included cleft palates, skeletal defects and deformed appendages, paws and tails. The dosages which were teratogenic in animals are 1 to 3 times the maximum recommended human therapeutic dose. In monkeys, divided doses of 40 mg/kg given between days 20 and 24 of gestation were not teratogenic.

5-fluorouracil has not been studied in animals for its effects on peri- and post-natal development. However, 5-fluorouracil has been shown to cross the placenta and enter into fetal circulation in the rat. Administration of 5-fluorouracil has resulted in increased resorptions and embryoletality in rats. In monkeys, maternal doses higher than 40 mg/kg resulted in abortion of all embryos exposed to 5-fluorouracil. Compounds which inhibit DNA, RNA and protein synthesis might be expected to have adverse effects on peri- and post-natal development.

REFERENCES

Pharmacology

Actions:

1. Boccardo F, Canobbio L. I. 5-fluorouracil, twenty-five years later. An appraisal. *Chemioterapia* 1983;2(2):88-96.
2. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. *Clin Pharmacokinet* 1989;4:215-37.
3. Parker WB, Cheng YC. Metabolism of action of 5-fluorouracil. *Pharmac Ther* 1990;48:381-95.

Pharmacokinetics:

1. Almersjö OE, et al. Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. *Acta Pharmacol Toxicol* 1980;46:329-36.
2. Ardalan B, Glazer R. An update on the biochemistry of 5-fluorouracil. *Cancer Treat Rev* 1981;8:157-67.
3. Bernadou J, et al. Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by ¹⁹F nuclear magnetic resonance. *Clin Chem* 1985;31:846-8.
4. Cano JP, et al. Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics. *Bull Cancer* 1979;66:67-74.
5. Chabner BA. Pyrimidine antagonists. In: Chabner BA, ed. *Pharmacologic principles of cancer treatment*. Philadelphia: NB Saunders, 1982:183-212.
6. Collins JM, et al. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. *Clin Pharmacol Ther* 1980;28:235-46.
7. Finch RE, et al. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. *Br J Clin Pharmacol* 1979;7:613-7.
8. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-FU administered orally, by rapid intravenous and by slow infusion. *Cancer Res* 1980;40:2223-8.
9. Sadee W, Wang CG. Research review: pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy. *Clin Pharmacokinet* 1977;2:437-50.

Therapeutics

Gastrointestinal Cancer:

1. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. *Cancer* 1989;63(6 Suppl):1036-44. (I11:I-2621)
2. Madajewicz S, Avvento L. Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies. *J Chemother* 1990;2 Suppl 1:33-7. (K22:K-6765)

Breast Cancer:

1. Chang AYC, Most C, Pandya KJ. Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. *Am J Clin Oncol* 1989;12:453-5. (I46:I-11518)

Pancreatic Cancer:

1. Tajiri H, Yoshimori M, Okazaki N, et al. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. *Oncology* 1991;48:18-21. (L08:L-2315)

Head and Neck Cancer:

1. Dreyfuss A, Clark J, Fallon B, et al. Continuous infusion cisplatin, 5-FU and high dose leucovorin (PFL) as induction chemotherapy for squamous cell carcinoma of the head and neck. In: Rubinstein E, et al, eds. *Recent advances in chemotherapy, anticancer section. Proceedings of the 16th International Congress of Chemotherapy*; 1989; Jerusalem, Israel. Tel Aviv: E Lewin-Epstein, 1989:826.1-3. (K22:K-6727)
2. Vokes EE, Choi KE, Schilsky RL, et al. Cisplatin, fluorouracil and high-dose leucovorin for recurrent or metastatic head and neck cancer. *J Clin Oncol* 1988;6:618-26. (H17:H-4355)

Continuous Venous Infusion

1. Hansen RM, Quebbemann E, Anderson T. 5-fluorouracil by protracted venous infusion. A review of current progress. *Oncology* 1989;46:245-50.
2. Lokich JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. *J Clin Oncol* 1989;7:425-32.

Combination Therapy

Leucovorin:

1. Palmieri G, Gridelli C, Airoma G, et al. Clinical trial with 5-fluorouracil and leucovorin. *J Chemother* 1990;(2 Suppl 1):41-6. (K22:K-6767)
2. Rustum YM. Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. *J Chemother* 1990;(2 Suppl 1):5-11. (K22:K-6761)

Methotrexate:

1. Bruckner HW, Cohen J. Methotrexate/5-FU in gastrointestinal and other cancers. *Semin Oncol* 1983;10(2 Suppl 2):32-9.
2. Marsh JC, Bertino JR, Katz KH, et al. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. *J Clin Oncol* 1991;9:371-80.

'Roferon'-A:

1. Wadler S. Clinical studies of 5-FU and Roferon-A in combination. In: Trends in interferon research. Proceedings of an interferon workshop; 1989 Oct 21; Florence, Italy. 1989:17-20. (K42:K-12307)
2. Wadler S, Schwartz E. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. *Cancer Res* 1990 15;50:3473-86.

Adriamycin:

1. Berken A, Greenblatt MN, Rosenthal DS, et al. High frequency low dose multiple drug chemotherapy in advanced metastatic breast cancer. *Cancer* 1982;49:2231-3.
2. Raschko JW, Johnson EA, Veno W, et al. Continuous infusion of 5-fluorouracil with bolus adriamycin and mitomycin and low dose cisplatin (FAMP) in the treatment of metastatic gastric carcinoma: an evaluation of efficacy and toxicity. *Cancer Invest* 1991;9:49-51. (L29:L-8373)

Safety

1. Crocker J, Jones EL. Haemolytic uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma. *J Clin Pathol* 1983;36:24-9.
2. Fabian CJ, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. *Invest New Drugs* 1990;8:57-63.

3. Folb, PI. Cytostatic and immunosuppressive drugs. In: Dukes MNG, ed. Meyler's side effects of drugs. New York: Elsevier, 1988;47:945.
4. Gradishar WJ, et al. 5-fluorouracil cardiotoxicity: a critical review. Ann Oncol 1990;1:409-14.
5. Jolivet J, et al. Microangiopathic hemolytic anemia, renal failure and non cardiogenic pulmonary edema: a chemotherapy induced syndrome. Cancer Treat Rep 1983;67:429-34.